uploads/2018/09/Chart-002-5-1.jpg

Shire’s Quarterly Revenue Trend

By

Updated

Shire’s revenue

Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.

The chart above compares Shire’s revenues since the first quarter of 2017.

Article continues below advertisement

Revenues in the second quarter

Shire reported revenue of $3.920 billion in the second quarter, a ~4.6% YoY rise in revenue compared to $3.746 billion in the second quarter of 2017. This revenue growth included a 6% increase in product sales to $3.809 billion partially offset by a 28% fall in royalty and other revenues to $111 million in the quarter.

Revenue performance in the second quarter

The performances of Shire’s various therapeutic areas in the second quarter were as follows:

  • Immunology products reported a 13% YoY rise in sales to $1.150 billion in the quarter.
  • Neuroscience products reported a 9% YoY rise in sales to $694 million in the quarter.
  • Hematology products reported a 1% YoY fall in sales to $951 million in the quarter.
  • Established brands reported a 36% YoY fall in sales to $219 million in the quarter.
  • Internal medicines reported a 61% YoY rise in sales to $233 million in the quarter.
  • Generic diseases products reported a 6% YoY rise in sales to $392 million in the quarter.
  • Ophthalmic products reported a 75% YoY rise in sales to $100 million in the quarter.
  • Oncology products reported a 14% YoY rise in sales to $71 million in the quarter.

The iShares NASDAQ Biotechnology ETF (IBB) holds 1.4% of its total investments in Shire, 1.7% in Incyte (INCY), 7.9% in Gilead Sciences (GILD), and 4.8% in Regeneron Pharmaceuticals (REGN).

Advertisement

More From Market Realist